Century Therapeutics (IPSC) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company developing allogeneic pluripotent stem cell therapies for autoimmune diseases and cancer, leveraging iPSC-derived NK and T cell platforms for scalable, off-the-shelf treatments.

• Proprietary platform includes CRISPR gene editing, protein engineering, Allo-Evasion™ technology, and advanced manufacturing for enhanced product performance and reduced costs.

• Lead candidate CNTY-101 is a CAR-iNK cell therapy in Phase 1 for B-cell mediated autoimmune diseases; lymphoma program discontinued in March 2025 for strategic reasons.

• Pipeline re-prioritized in March 2025 to focus on three core preclinical iT cell programs targeting autoimmune diseases, B cell malignancies, and solid tumors.

• Vision is to become a fully integrated biotech commercializing transformative allogeneic cell therapies for serious diseases with high unmet need.

Risk factors and disclosures

• Risks include ability to raise capital, early clinical stage of business, dependence on lead candidate, competition, regulatory challenges, and reliance on key collaborations.

• Additional risks relate to market volatility, macroeconomic factors, public perception of cell therapies, and intellectual property protection.

• Investors are directed to review risk factors in the latest Annual and Quarterly Reports and any prospectus supplement.

Market opportunity and competitive landscape

• Off-the-shelf iPSC-derived therapies aim to address limitations of first-generation cell therapies, offering broader patient access and scalable manufacturing.

• Programs target high unmet need in autoimmune diseases, B cell malignancies, and solid tumors, with potential for significant differentiation.